Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Trial details
- Registry ID
- NCT06982521
- Phase
- Phase 3
The FDA approved Capivasertib (TRUQAP) on 16 Nov 2023.
Drug identity checked against registry records
Also recorded as TRUQAP
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 | RLAY | Phase 3 | Recruiting | 2028-04-30Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-11-16Day | Capivasertib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA218197", "applicant_as_listed_by_fda": "ASTRAZENECA", "brand_names": ["TRUQAP"], "active_ingredients": ["CAPIVASERTIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20231116", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |